Fan Lin1, Bin-Ling Chen2, Yi-Zheng Wang1, Dong Gao3, Jun Song4, T J Kaptchuk5, Ke-Ji Chen6. 1. College of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China. 2. The Second Hospital of Longyan, Longyan, Fujian Province, 364000, China. 3. College of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China. 976558160@qq.com. 4. Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, 100700, China. junsong86@sohu.com. 5. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. 6. Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Abstract
OBJECTIVE: To compare the angiogenesis behaviors of vascular endothelial growth factor (VEGF) and Chinese medicine Xuefu Zhuyu Decoction (, XZD) treatments. METHODS: Human microvascular endothelial cells (HMEC-1) were treated with various concentrations of either XZD-containing serum (XZD-CS) or VEGF for 24, 48, and 72 h, respectively. Cell viability, proliferation, migration, adhesion, and in vitro tube formation assays were used to assess their angiogenic effects. RESULTS: VEGF promoted all cellular phases involved in angiogenesis including cell viability, proliferation, migration, adhesion, and tube formation (<0.05 or <0.01). Unlike the continuous promotion effects of VEGF at the above stages, XZD inhibited cell viability and proliferation (<0.05 or <0.01) and only promoted tube formation in the early phase of angiogenesis (<0.01). CONCLUSIONS: These two medications promote different angiogenesis behaviors, which might be an important reason for their distinct therapeutic profile in clinical usage.
OBJECTIVE: To compare the angiogenesis behaviors of vascular endothelial growth factor (VEGF) and Chinese medicine Xuefu Zhuyu Decoction (, XZD) treatments. METHODS:Human microvascular endothelial cells (HMEC-1) were treated with various concentrations of either XZD-containing serum (XZD-CS) or VEGF for 24, 48, and 72 h, respectively. Cell viability, proliferation, migration, adhesion, and in vitro tube formation assays were used to assess their angiogenic effects. RESULTS:VEGF promoted all cellular phases involved in angiogenesis including cell viability, proliferation, migration, adhesion, and tube formation (<0.05 or <0.01). Unlike the continuous promotion effects of VEGF at the above stages, XZD inhibited cell viability and proliferation (<0.05 or <0.01) and only promoted tube formation in the early phase of angiogenesis (<0.01). CONCLUSIONS: These two medications promote different angiogenesis behaviors, which might be an important reason for their distinct therapeutic profile in clinical usage.
Authors: E R Schwarz; M T Speakman; M Patterson; S S Hale; J M Isner; L H Kedes; R A Kloner Journal: J Am Coll Cardiol Date: 2000-04 Impact factor: 24.094
Authors: Dong Gao; Jun Song; Juan Hu; Jiumao Lin; Liangpu Zheng; Jing Cai; Jian Du; Keji Chen Journal: Zhongguo Zhong Xi Yi Jie He Za Zhi Date: 2005-10
Authors: Kyoko Ohno-Matsui; Akira Hirose; Satoru Yamamoto; Jina Saikia; Naoyuki Okamoto; Peter Gehlbach; Elia J Duh; Sean Hackett; Michelle Chang; Dean Bok; Donald J Zack; Peter A Campochiaro Journal: Am J Pathol Date: 2002-02 Impact factor: 4.307